Bashar A. Alkhalidi

ORCID: 0000-0002-6024-7158
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Drug Solubulity and Delivery Systems
  • Analytical Methods in Pharmaceuticals
  • Advanced Drug Delivery Systems
  • Antibiotics Pharmacokinetics and Efficacy
  • Pharmaceutical studies and practices
  • Crystallization and Solubility Studies
  • Pneumonia and Respiratory Infections
  • Lung Cancer Diagnosis and Treatment
  • Surgical Sutures and Adhesives
  • Tuberculosis Research and Epidemiology

University of Jordan
2008-2017

The objective of this study was to evaluate the in vitro behavior different clarithromycin granular suspensions based on a developed vitro-in vivo correlation model, using one reference and two test formulations. In release rate data were obtained for each product USP apparatus II, operated at 50 rpm under pH conditions. dissolution efficiency used analyze data. performed six healthy male volunteers fasting condition. Correlation made between absorption. A linear model percent absorbed...

10.3109/10837450903188493 article EN Pharmaceutical Development and Technology 2010-05-04

Context: The success of the development controlled release, multilayered, multiparticulate dosage form a high-dose, highly-soluble drug is dependent upon proper material and processing choices.Objective: To develop release diltiazem hydrochloride using active layering coating.Methods: Active was achieved by spraying solution onto sugar cores polyvinyl alcohol – polyethylene glycol as binder. Layered pellets with highest loading lowest binder content were coated aqueous dispersions acetate...

10.3109/10837450.2013.805778 article EN Pharmaceutical Development and Technology 2013-06-14

The aim of this study was to understand the impact COVID-19 pandemic on treatment patterns for patients with stage III unresectable non-small cell lung cancer (uNSCLC). This a retrospective chart review uNSCLC diagnosed between 1 October 2017 and 31 May 2021 in France, Germany, Italy, Spain, Canada, USA. Of 351 enrolled (median age 70 years [range 44-91]; 63.5% male), 88 263 were treated prior (Cohort 1) during 2) pandemic, respectively. majority Cohort (89.8%) 2 (82.5%) received...

10.1016/j.esmoop.2024.102911 article EN cc-by-nc-nd ESMO Open 2024-03-01
Coming Soon ...